Skip to content

Study · Animal study (in vivo) · rat · 2011

2 results

New, potent, selective, and short-acting peptidic V1a receptor agonists.

Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD

Journal of medicinal chemistry20 Jun 2011Cited by 38 (Europe PMC)

PMID21688787 (opens in a new tab)DOI10.1021/jm200278m (opens in a new tab)PepBankPUB-21688787
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, compound 45 (FE 202158) was as short-acting as arginine vasopressin.

    In plain wordsIn rats, FE 202158 had a short duration of blood pressure action similar to arginine vasopressin.

    Peptide
    Selepressin
    Outcome
    Direction not reportedDuration of vasopressive action
    Study

    ratsn: not reported in source

    Comparator
    Arginine vasopressin
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intravenous bolusAs given in this study (rats).

    Source sentences

    Summary
    Analogues 31, 34, 45, and 49 were as short-acting as AVP.
    2 context sentences
    Summary · context
    were tested by intravenous bolus in rats for duration of vasopressive action.
    Summary · context
    Compound 45, FE 202158, is currently undergoing clinical trials in septic shock.
  2. 02LabOther designActivity measurement

    In functional assays, FE 202158 was among the most potent and selective compounds reported.

    In plain wordsIn lab tests, FE 202158 was among the most potent and selective compounds reported.

    Peptide
    Selepressin
    Outcome
    Direction not reportedPotency and selectivity in functional assays
    Study

    n: not reported in source

    In vitro functional assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The most potent and selective compounds in in vitro functional assays (e.g., [Phe(2),Ile(3),Asn(Me(2))(4),Orn(8)]VP (31), [Phe(2),Ile(3),Asn((CH(2))(3)OH)(4),Orn(8)]VP (34), [Phe(2),Ile(3),Hgn(4),Orn(iPr)(8)]VP (45)
    1 context sentence
    Summary · context
    Compound 45, FE 202158, is currently undergoing clinical trials in septic shock.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.